New combo therapy aims to control advanced lung cancer

NCT ID NCT06217757

First seen May 12, 2026 · Last updated May 14, 2026 · Updated 1 time

Summary

This study tests a new treatment for people with a specific type of advanced small cell lung cancer (SLFN-11 positive). The treatment combines low-dose radiation, chemotherapy, and two drugs (sugemalimab and olaparib). The goal is to see if this combination is safe and helps control the cancer longer. About 45 adults who have not had prior treatment for this stage of cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610044, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.